Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30073575 | 1.00 | THRB (1.00) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25633990 | 0.87 | THRB (0.77) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25633428 | 0.87 | THRB (0.77) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25633373 | 0.86 | THRB (0.76) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25634032 | 0.83 | THRB (0.71) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25634028 | 0.82 | THRB (0.69) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL30073618 | 0.81 | THRB (0.68) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25633353 | 0.81 | THRB (0.68) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25634017 | 0.80 | THRB (0.67) | THRBTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL25634263 | 0.79 | THRB (0.65) | THRBTP53RXFP1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| WO-2021219784-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | THRB 277/4885TP53 1754/4885RXFP1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.